# Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)

> **NCT07045909** · PHASE2 · RECRUITING · sponsor: **PETHEMA Foundation** · enrollment: 30 (estimated)

## Conditions studied

- De Novo Multiple Myeloma
- Anitocabtagene Autoleucel

## Interventions

- **DRUG:** Daratumumab
- **DRUG:** Isatuximab
- **DRUG:** Bortezomib
- **DRUG:** Lenalidomide
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Anitocabtagene Autoleucel

## Key facts

- **NCT ID:** NCT07045909
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-30
- **Primary completion:** 2028-03-31
- **Final completion:** 2030-03-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07045909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07045909, "Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07045909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*